Bristol/Pfizer's Apixaban Bests Lovenox At Preventing VTE In Knee Surgery In Second Attempt
This article was originally published in The Pink Sheet Daily
Executive Summary
After failing to show non-inferiority in ADVANCE I, the Bristol/Pfizer anticoagulant was soundly superior to enoxaparin in ADVANCE II.